Eye­ing RNAi po­ten­tial in can­cer and fi­bro­sis, trans-Pa­cif­ic biotech Sir­naomics lines up $47M Se­ries C

With sup­port from a syn­di­cate that speaks to its ex­ten­sive Chi­na ties, Gaithers­burg, MD-based Sir­naomics has raised an ad­di­tion­al $22 mil­lion to close out its C round.

As its name sug­gests, the biotech is fo­cused on all things re­lat­ed to small in­ter­fer­ing RNA (siR­NA), the key mol­e­cule mR­NA si­lenc­ing. Pop­u­lar­ized by Al­ny­lam, which scored the field’s first FDA ap­proval, siR­NA kicks off ac­tion in the RNA-in­duced si­lenc­ing com­plex, which then goes on to cleave a spe­cif­ic mR­NA, there­by down­reg­u­lat­ing tar­get genes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER